Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | DREAMM-5: belamaf therapy in R/R myeloma

Paul Richardson • 6 Dec 2020
ASH 2020
Multiple Myeloma Antibodies Belantamab mafodotin Nirogacestat
DREAMM-5

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, introduces the DREAMM-5 trial (NCT04126200) which explores the use of belantamab mafodotin (Belamaf) in combination with four different novel agents in relapsed/refractory multiple myeloma (R/R) myeloma. Belamaf’s multimodal mechanism of action has the potential to achieve synergistic effects when combined with these other agents; enhancing anti-myeloma activity without compromising safety. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Paul Richardson

1:35
Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
Paul Richardson • 29 Sep 2023
2:51
ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma
Paul Richardson • 29 Sep 2023
7:24
Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson • 29 Sep 2023
2:59
Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals